Baseline data of LADA and type 2 diabetic patients
| . | Type 2 diabetes . | Low GADA titer LADA . | High GADA titer LADA . |
|---|---|---|---|
| n = 28 | n = 42 | n = 25 | |
| Age (years) | 53.6 ± 10.1 | 52.2 ± 9.0 | 50.6 ± 11.7 |
| Sex | |||
| Male | 18 | 29 | 15 |
| Female | 10 | 13 | 10 |
| Duration (years) | 2.2 ± 0.7 | 1.8 ± 0.9 | 2.0 ± 1.3 |
| BMI (kg/m2) | 24.4 ± 2.9 | 24.6 ± 2.5 | 23.5 ± 2.6 |
| Metformin (yes/no), n | 22/6 | 20/22* | 6/19* |
| Rosiglitazone (yes/no), n | 10/18 | 19/23 | 15/10 |
| Metformin and rosiglitazone (yes/no), n | 9/19 | 11/31 | 3/22 |
| Insulin (yes/no), n | 6/22 | 22/20* | 20/5* |
| Insulin dose (units/kg/day) | 0.34 | 0.34 | 0.35 |
| HbA1c (%) | 6.4 ± 1.2 | 6.8 ± 1.0 | 6.9 ± 1.1 |
| HbA1c (mmol/mol) | 46 ± 13 | 51 ± 11 | 52 ± 12 |
| HOMA2-IR | 1.1 (0.5, 2.3) | 1.2 (0.6, 3.4) | 1.3 (0.5, 5.3) |
| FCP (nmol/L) | 0.47 (0.22, 0.90) | 0.48 (0.25, 1.04) | 0.49 (0.20, 1.07) |
| PCP (nmol/L) | 1.74 (0.42, 3.64) | 1.80 (0.48, 3.55) | 1.55 (0.73, 3.67) |
| ΔCP (PCP – FCP) (nmol/L) | 1.22 (0.14, 2.74) | 1.27 (0.00, 2.44) | 1.24 (0.11, 3.28) |
| HLA protective haplotypes, % (n/N) | 18.2 (4/22) | 17.6 (6/34) | 18.8 (3/16) |
| HLA susceptibility haplotypes, % (n/N) | 50 (8/16) | 50 (17/34) | 50 (11/22) |
| . | Type 2 diabetes . | Low GADA titer LADA . | High GADA titer LADA . |
|---|---|---|---|
| n = 28 | n = 42 | n = 25 | |
| Age (years) | 53.6 ± 10.1 | 52.2 ± 9.0 | 50.6 ± 11.7 |
| Sex | |||
| Male | 18 | 29 | 15 |
| Female | 10 | 13 | 10 |
| Duration (years) | 2.2 ± 0.7 | 1.8 ± 0.9 | 2.0 ± 1.3 |
| BMI (kg/m2) | 24.4 ± 2.9 | 24.6 ± 2.5 | 23.5 ± 2.6 |
| Metformin (yes/no), n | 22/6 | 20/22* | 6/19* |
| Rosiglitazone (yes/no), n | 10/18 | 19/23 | 15/10 |
| Metformin and rosiglitazone (yes/no), n | 9/19 | 11/31 | 3/22 |
| Insulin (yes/no), n | 6/22 | 22/20* | 20/5* |
| Insulin dose (units/kg/day) | 0.34 | 0.34 | 0.35 |
| HbA1c (%) | 6.4 ± 1.2 | 6.8 ± 1.0 | 6.9 ± 1.1 |
| HbA1c (mmol/mol) | 46 ± 13 | 51 ± 11 | 52 ± 12 |
| HOMA2-IR | 1.1 (0.5, 2.3) | 1.2 (0.6, 3.4) | 1.3 (0.5, 5.3) |
| FCP (nmol/L) | 0.47 (0.22, 0.90) | 0.48 (0.25, 1.04) | 0.49 (0.20, 1.07) |
| PCP (nmol/L) | 1.74 (0.42, 3.64) | 1.80 (0.48, 3.55) | 1.55 (0.73, 3.67) |
| ΔCP (PCP – FCP) (nmol/L) | 1.22 (0.14, 2.74) | 1.27 (0.00, 2.44) | 1.24 (0.11, 3.28) |
| HLA protective haplotypes, % (n/N) | 18.2 (4/22) | 17.6 (6/34) | 18.8 (3/16) |
| HLA susceptibility haplotypes, % (n/N) | 50 (8/16) | 50 (17/34) | 50 (11/22) |
Data are shown as mean ± SD, median (minimum, maximum), or as indicated.
*P < 0.05 compared with type 2 diabetic group.